Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.50 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30996674 | 0.86 | TSHR (0.42) | HCAR2HCAR3ALPL | |
| SCHEMBL17224867 | 0.83 | MAPK1 (0.57) | HCAR2ALPL | |
| SCHEMBL16619843 | 0.83 | KMT2A (0.51) | — | |
| SCHEMBL31530616 | 0.83 | ALDH1A1 (0.49) | HCAR2ALPL | |
| SCHEMBL16619632 | 0.81 | MAPK8 (0.46) | HCAR2ALPL | |
| SCHEMBL16445300 | 0.81 | HCAR2 (0.60) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5317023 | 0.79 | HCAR2 (0.58) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL28111052 | 0.78 | HCAR2 (0.45) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5599447 | 0.74 | HCAR2 (0.75) | HCAR2DAOHCAR3 | |
| SCHEMBL22777728 | 0.72 | MCL1 (0.48) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | claimed |
| EP-3486246-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | Galapagos N.V. (BE) | 2019-05-22 | — | — | EP | claimed |
| EP-3030568-B1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | GALAPAGOS NV (BE) | 2018-09-19 | — | — | EP | claimed |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | claimed |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | claimed |
| EP-3030568-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | Galapagos NV (BE) | 2016-06-15 | — | — | EP | claimed |
| US-9351955-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-05-31 | — | — | US | claimed |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | claimed |
| US-9133210-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2015-09-15 | — | — | US | claimed |
| WO-2015018823-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | GALAPAGOS NV (BE) | 2015-02-12 | — | — | WO | claimed |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | claimed |
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2015018823-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | GALAPAGOS NV (BE) | 2015-02-12 | — | — | WO | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568867-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | CFTR, ABCB11, PKD1 | HCAR2 1995/4885DAO 3496/4885HCAR3 1160/4885 |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | HCAR2 1890/4885DAO 3619/4885HCAR3 1125/4885 |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | HCAR2 1890/4885DAO 3619/4885HCAR3 1125/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | CFTR, ABCB11, ABCC5 | HCAR2 1890/4885DAO 3619/4885HCAR3 1125/4885 |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | HCAR2 1890/4885DAO 3619/4885HCAR3 1125/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.